NCCN CLINICAL PRACTICE GUIDELINES IN ONCOLOGY Management of Immunotherapy- Related Toxicities, Version 1.2019

The aim of the NCCN Guidelines for Management of ImmunotherapyRelated Toxicities is to provide guidance on the management of immune-related adverse events resulting from cancer immunotherapy. The NCCN Management of Immunotherapy-Related Toxicities Panel is an interdisciplinary group of representatives from NCCN Member Institutions and ASCO, consisting of medical and hematologic oncologists with expertise in a wide array of disease sites, and experts from the fields of dermatology, gastroenterology, neurooncology, nephrology, emergency medicine, cardiology, oncology nursing, and patient advocacy. Several panel representatives are members of the Society for Immunotherapy of Cancer (SITC). The initial version of the NCCN Guidelines was designed in general alignment with recommendations published by ASCO and SITC. The content featured in this issue is an excerpt of the recommendations for managing toxicity related to immune checkpoint blockade and a review of existing evidence. For the full version of the NCCN Guidelines, including recommendations for managing toxicities related to chimeric antigen receptor T-cell therapy, visit NCCN.org. J Natl Compr Canc Netw 2019;17(3):255–289 doi: 10.6004/jnccn.2019.0013 NCCN CATEGORIES OF EVIDENCE AND CONSENSUS Category 1: Based upon high-level evidence, there is uniform NCCN consensus that the intervention is appropriate. Category 2A: Based upon lower-level evidence, there is uniform NCCN consensus that the intervention is appropriate. Category 2B: Based upon lower-level evidence, there is NCCN consensus that the intervention is appropriate. Category 3: Based upon any level of evidence, there is major NCCN disagreement that the intervention is appropriate. All recommendations are category 2A unless otherwise noted. Clinical trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

[1]  Dennis Grauer,et al.  Corticosteroids for the management of immune-related adverse events in patients receiving checkpoint inhibitors , 2019, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

[2]  R. Sullivan,et al.  Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis , 2018, JAMA oncology.

[3]  Ami A. Shah,et al.  Clinical presentation of immune checkpoint inhibitor-induced inflammatory arthritis differs by immunotherapy regimen. , 2018, Seminars in arthritis and rheumatism.

[4]  Gregory Riely,et al.  Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  R. Bresalier,et al.  Endoscopic and Histologic Features of Immune Checkpoint Inhibitor-Related Colitis. , 2018, Inflammatory bowel diseases.

[6]  N. Ramaiya,et al.  Multimodality imaging of endocrine immune related adverse events: a primer for radiologists. , 2018, Clinical imaging.

[7]  Mark S. Anderson,et al.  Collateral Damage: Insulin-Dependent Diabetes Induced With Checkpoint Inhibitors , 2018, Diabetes.

[8]  C. Shields,et al.  CHECKPOINT INHIBITOR IMMUNE THERAPY: Systemic Indications and Ophthalmic Side Effects , 2018, Retina.

[9]  A. Rosenberg,et al.  Hepatotoxicity of immune checkpoint inhibitors: An evolving picture of risk associated with a vital class of immunotherapy agents , 2018, Liver international : official journal of the International Association for the Study of the Liver.

[10]  R. Pazdur,et al.  FDA analysis of pembrolizumab trials in multiple myeloma: Immune related adverse events (irAEs) and response. , 2018 .

[11]  D. Samuel,et al.  Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors. , 2018, Journal of hepatology.

[12]  V. Sibaud.  Dermatologic Reactions to Immune Checkpoint Inhibitors , 2018, American Journal of Clinical Dermatology.

[13]  O. Rahma,et al.  Gastrointestinal and Hepatic Toxicities of Checkpoint Inhibitors: Algorithms for Management. , 2018, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

[14]  U. Topaloglu,et al.  Severe neurologic complications of immune checkpoint inhibitors: a single-center review , 2018, Journal of Neurology.

[15]  G. Raju,et al.  Immune-checkpoint inhibitor-induced diarrhea and colitis in patients with advanced malignancies: retrospective review at MD Anderson , 2018, Journal of Immunotherapy for Cancer.

[16]  R. Sullivan,et al.  Myocarditis in Patients Treated With Immune Checkpoint Inhibitors. , 2018, Journal of the American College of Cardiology.

[17]  S. Laurie,et al.  The Risk of Diarrhea and Colitis in Patients With Advanced Melanoma Undergoing Immune Checkpoint Inhibitor Therapy: A Systematic Review and Meta-Analysis , 2018, Journal of immunotherapy.

[18]  R. Rosell,et al.  Clinical assessment of immune-related adverse events , 2018, Therapeutic advances in medical oncology.

[19]  M. Hellmann,et al.  Adverse Events Associated with Immune Checkpoint Blockade. , 2018, The New England journal of medicine.

[20]  Bénédicte Lebrun-Vignes,et al.  Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis , 2018, The Lancet.

[21]  J. Schachter,et al.  Rheumatic manifestations among cancer patients treated with immune checkpoint inhibitors. , 2018, Autoimmunity reviews.

[22]  M. Atkins,et al.  Emerging Role of Vedolizumab in Managing Refractory Immune Checkpoint Inhibitor–Induced Enteritis , 2018, ACG case reports journal.

[23]  K. Kelly,et al.  Safety profile of avelumab in patients with advanced solid tumors: A pooled analysis of data from the phase 1 JAVELIN solid tumor and phase 2 JAVELIN Merkel 200 clinical trials , 2018, Cancer.

[24]  Y. Chae,et al.  Cancer immunotherapy in a neglected population: The current use and future of T-cell-mediated checkpoint inhibitors in organ transplant patients. , 2018, Cancer treatment reviews.

[25]  M. Suarez‐Almazor,et al.  Use of Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Autoimmune Disease , 2018, Annals of Internal Medicine.

[26]  F. Khuri,et al.  Comparison of the toxicity profile of PD‐1 versus PD‐L1 inhibitors in non–small cell lung cancer: A systematic analysis of the literature , 2018, Cancer.

[27]  M. Lotem,et al.  Neurologic complications of immune checkpoint inhibitors , 2018, Journal of Neuro-Oncology.

[28]  Matthew D. Hellmann,et al.  Immune‐Related Adverse Events Associated with Immune Checkpoint Blockade , 2018, The New England journal of medicine.

[29]  E. Rozeman,et al.  Immune checkpoint inhibition-related colitis: symptoms, endoscopic features, histology and response to management , 2018, ESMO Open.

[30]  J. Wolchok,et al.  Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  F. Dhermain,et al.  Combined irradiation and targeted therapy or immune checkpoint blockade in brain metastases: toxicities and efficacy , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[32]  D. Ricard,et al.  Neurological toxicities associated with immune-checkpoint inhibitors , 2017, Current opinion in neurology.

[33]  Douglas B. Johnson,et al.  Smoldering myocarditis following immune checkpoint blockade , 2017, Journal of Immunotherapy for Cancer.

[34]  M. Suarez‐Almazor,et al.  Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group , 2017, Journal of Immunotherapy for Cancer.

[35]  K. O'Byrne,et al.  Pembrolizumab‐Induced Encephalopathy: A Review of Neurological Toxicities with Immune Checkpoint Inhibitors , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[36]  C. V. van Herpen,et al.  Nivolumab-associated Nephrotic Syndrome in a Patient With Renal Cell Carcinoma: A Case Report , 2017, Journal of immunotherapy.

[37]  Ami A. Shah,et al.  Rheumatic and Musculoskeletal Immune‐Related Adverse Events Due to Immune Checkpoint Inhibitors: A Systematic Review of the Literature , 2017, Arthritis care & research.

[38]  M. Fernández-Figueras,et al.  Hair Repigmentation During Immunotherapy Treatment With an Anti–Programmed Cell Death 1 and Anti–Programmed Cell Death Ligand 1 Agent for Lung Cancer , 2017, JAMA dermatology.

[39]  N. Staff,et al.  Neurological Complications Associated With Anti–Programmed Death 1 (PD-1) Antibodies , 2017, JAMA neurology.

[40]  L. Siu,et al.  Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[41]  W. Barry,et al.  Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis , 2017, JAMA Oncology.

[42]  G. Widmann,et al.  Imaging Features of Toxicities by Immune Checkpoint Inhibitors in Cancer Therapy , 2017, Current Radiology Reports.

[43]  D. Schadendorf,et al.  Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma , 2017, The New England journal of medicine.

[44]  J. Coward,et al.  Myasthenia gravis: An emerging toxicity of immune checkpoint inhibitors. , 2017, European journal of cancer.

[45]  M. Atkins,et al.  Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial. , 2017, The Lancet. Oncology.

[46]  H. McArthur,et al.  Combined Radiation Therapy and Immune Checkpoint Blockade Therapy for Breast Cancer. , 2017, International journal of radiation oncology, biology, physics.

[47]  A. Enk,et al.  Severe Ocular Myositis After Ipilimumab Treatment for Melanoma: A Report of 2 Cases. , 2017, Journal of immunotherapy.

[48]  J. Larkin,et al.  Novel combination strategies for enhancing efficacy of immune checkpoint inhibitors in the treatment of metastatic solid malignancies , 2017, Expert opinion on pharmacotherapy.

[49]  D. Schadendorf,et al.  Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  A. Iyer,et al.  PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome , 2017, Front. Pharmacol..

[51]  Douglas B. Johnson,et al.  Incidence of immune checkpoint inhibitor-related colitis in solid tumor patients: A systematic review and meta-analysis , 2017, Oncoimmunology.

[52]  C. Garbe,et al.  Severe hepatitis under combined immunotherapy: Resolution under corticosteroids plus anti-thymocyte immunoglobulins. , 2017, European journal of cancer.

[53]  P. Kamath,et al.  Hepatotoxicity After Immune Checkpoint Inhibitor Therapy in Melanoma: Natural Progression and Management , 2017, American journal of clinical oncology.

[54]  A. Shinagare,et al.  Imaging of hepatic toxicity of systemic therapy in a tertiary cancer centre: chemotherapy, haematopoietic stem cell transplantation, molecular targeted therapies, and immune checkpoint inhibitors. , 2017, Clinical radiology.

[55]  A. Kittai,et al.  Immune Checkpoint Inhibitors in Organ Transplant Patients , 2017, Journal of immunotherapy.

[56]  E. Plimack,et al.  Endocrine-related adverse events associated with immune checkpoint blockade and expert insights on their management. , 2017, Cancer treatment reviews.

[57]  B. Carneiro,et al.  Clinical features, diagnostic challenges, and management strategies in checkpoint inhibitor-related pneumonitis , 2017, Cancer management and research.

[58]  X. Mariette,et al.  Rheumatoid arthritis and polymyalgia rheumatica occurring after immune checkpoint inhibitor treatment , 2017, Annals of the rheumatic diseases.

[59]  J. Larkin,et al.  Neurologic Serious Adverse Events Associated with Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Including a Case Series of Encephalitis. , 2017, The oncologist.

[60]  Ami A. Shah,et al.  Inflammatory Arthritis: A Newly Recognized Adverse Event of Immune Checkpoint Blockade , 2017, The oncologist.

[61]  R. Motzer,et al.  Immune‐related alopecia (areata and universalis) in cancer patients receiving immune checkpoint inhibitors , 2017, The British journal of dermatology.

[62]  D. Fisher,et al.  Immune and molecular correlates in melanoma treated with immune checkpoint blockade , 2017, Cancer.

[63]  D. Schadendorf,et al.  Management of gastrointestinal (GI) toxicity associated with nivolumab (NIVO) plus ipilimumab (IPI) or IPI alone in phase II and III trials in advanced melanoma (MEL). , 2017 .

[64]  W. Miller,et al.  Reversal of Autoimmune Toxicity and Loss of Tumor Response by Interleukin-17 Blockade. , 2017, The New England journal of medicine.

[65]  P. Mazzone,et al.  Incidence of Pneumonitis With Use of Programmed Death 1 and Programmed Death‐Ligand 1 Inhibitors in Non‐Small Cell Lung Cancer: A Systematic Review and Meta‐Analysis of Trials , 2017, Chest.

[66]  D. Ang,et al.  Biologic Therapies for Autoimmune and Connective Tissue Diseases. , 2017, Immunology and allergy clinics of North America.

[67]  D. Schadendorf,et al.  Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial. , 2017, The Lancet. Oncology.

[68]  N. Agarwal,et al.  Incidence of Immune-Related Adverse Events with Program Death Receptor-1- and Program Death Receptor-1 Ligand-Directed Therapies in Genitourinary Cancers , 2017, Front. Oncol..

[69]  J. Wolchok,et al.  Cancer immunotherapy — immune checkpoint blockade and associated endocrinopathies , 2017, Nature Reviews Endocrinology.

[70]  A. Gesierich,et al.  Programmed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunity. , 2017, European journal of cancer.

[71]  S. Brant,et al.  Colonic ulcerations may predict steroid-refractory course in patients with ipilimumab-mediated enterocolitis , 2017, World journal of gastroenterology.

[72]  C. Rudin,et al.  Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[73]  S. Cuzzubbo,et al.  Neurological adverse events associated with immune checkpoint inhibitors: Review of the literature. , 2017, European journal of cancer.

[74]  D. Schadendorf,et al.  Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[75]  T. Berg,et al.  Managing immune checkpoint-inhibitor-induced severe autoimmune-like hepatitis by liver-directed topical steroids. , 2017, Journal of hepatology.

[76]  Y. Horio.  [Management of Toxicities of Immune Checkpoint Inhibitors]. , 2017, Gan to kagaku ryoho. Cancer & chemotherapy.

[77]  T. Choueiri,et al.  Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients , 2017, Cancer Immunology Research.

[78]  H. Oweira,et al.  Immune-related ocular toxicities in solid tumor patients treated with immune checkpoint inhibitors: a systematic review , 2017, Expert review of anticancer therapy.

[79]  A. Carneiro,et al.  Vedolizumab treatment for immune checkpoint inhibitor-induced enterocolitis , 2017, Cancer Immunology, Immunotherapy.

[80]  Y. Fujisawa,et al.  Severe hepatitis arising from ipilimumab administration, following melanoma treatment with nivolumab. , 2017, Japanese journal of clinical oncology.

[81]  P. Ott,et al.  Combining forces: the promise and peril of synergistic immune checkpoint blockade and targeted therapy in metastatic melanoma , 2017, Cancer and Metastasis Reviews.

[82]  M. Garg,et al.  Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy , 2017, Front. Pharmacol..

[83]  R. Bresalier,et al.  Gastrointestinal and Hepatic Complications of Immune Checkpoint Inhibitors , 2017, Current Gastroenterology Reports.

[84]  K. Jhaveri,et al.  Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review , 2017, American Journal of Nephrology.

[85]  C. Rudin,et al.  Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[86]  A. Giobbie-Hurder,et al.  Incidence of Programmed Cell Death 1 Inhibitor-Related Pneumonitis in Patients With Advanced Cancer: A Systematic Review and Meta-analysis. , 2016, JAMA oncology.

[87]  M. Cosottini,et al.  Hypophysitis Secondary to Cytotoxic T-Lymphocyte-Associated Protein 4 Blockade: Insights into Pathogenesis from an Autopsy Series. , 2016, The American journal of pathology.

[88]  J. Mazières,et al.  Acute interstitial nephritis related to immune checkpoint inhibitors , 2016, British Journal of Cancer.

[89]  J. Seidman,et al.  Fulminant Myocarditis with Combination Immune Checkpoint Blockade. , 2016, The New England journal of medicine.

[90]  G. Linette,et al.  Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. , 2016, The Lancet. Oncology.

[91]  L. Sequist,et al.  Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. , 2016, The Lancet. Oncology.

[92]  A. Hauschild,et al.  Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy. , 2016, The New England journal of medicine.

[93]  M. Postow,et al.  Treatment of the Immune-Related Adverse Effects of Immune Checkpoint Inhibitors: A Review. , 2016, JAMA oncology.

[94]  R. Sullivan,et al.  Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[95]  S. Fishbane,et al.  Adverse Renal Effects of Novel Molecular Oncologic Targeted Therapies: A Narrative Review , 2016, Kidney international reports.

[96]  U. Maggiore,et al.  The Bad and the Good News on Cancer Immunotherapy: Implications for Organ Transplant Recipients. , 2016, Advances in Chronic Kidney Disease.

[97]  D. Leaf,et al.  Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors. , 2016, Kidney international.

[98]  G. Uzel,et al.  CHAI and LATAIE: new genetic diseases of CTLA-4 checkpoint insufficiency. , 2016, Blood.

[99]  M. Brown,et al.  Vedolizumab: a novel treatment for ipilimumab-induced colitis , 2016, BMJ Case Reports.

[100]  Hussein Tawbi,et al.  Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy , 2016, Journal of Immunotherapy for Cancer.

[101]  S. Gettinger,et al.  Association of Acute Interstitial Nephritis With Programmed Cell Death 1 Inhibitor Therapy in Lung Cancer Patients. , 2016, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[102]  Matthieu Texier,et al.  Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination , 2016, Nature Reviews Clinical Oncology.

[103]  E. Lipson,et al.  Association of Autoimmune Encephalitis With Combined Immune Checkpoint Inhibitor Treatment for Metastatic Cancer. , 2016, JAMA neurology.

[104]  S. Corsello,et al.  Endocrinological side-effects of immune checkpoint inhibitors , 2016, Current opinion in oncology.

[105]  J. Antoun,et al.  Ocular and orbital side-effects of checkpoint inhibitors: a review article , 2016, Current opinion in oncology.

[106]  D. Jäger,et al.  Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. , 2016, The Lancet. Oncology.

[107]  J. Taieb,et al.  Checkpoint inhibitors and gastrointestinal immune-related adverse events , 2016, Current opinion in oncology.

[108]  M. Postow,et al.  Immune checkpoint inhibitor combinations in solid tumors: opportunities and challenges. , 2016, Immunotherapy.

[109]  Ami A. Shah,et al.  Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab , 2016, Annals of the rheumatic diseases.

[110]  J. Utikal,et al.  Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy. , 2016, European journal of cancer.

[111]  J. Wolchok,et al.  Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor. , 2016, European journal of cancer.

[112]  J. Utikal,et al.  Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy. , 2016, European journal of cancer.

[113]  N. Dunbar,et al.  Guidelines on the Use of Therapeutic Apheresis in Clinical Practice–Evidence‐Based Approach from the Writing Committee of the American Society for Apheresis: The Seventh Special Issue , 2016, Journal of clinical apheresis.

[114]  L. Riella,et al.  Severe acute interstitial nephritis after combination immune-checkpoint inhibitor therapy for metastatic melanoma , 2016, Clinical kidney journal.

[115]  C. Berking,et al.  Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy. , 2016, Cancer treatment reviews.

[116]  J. Wargo,et al.  Targeted Therapies Combined With Immune Checkpoint Therapy , 2016, Cancer journal.

[117]  J. Wolchok,et al.  Autoimmune Bullous Skin Disorders with Immune Checkpoint Inhibitors Targeting PD-1 and PD-L1 , 2016, Cancer Immunology Research.

[118]  J. Soria,et al.  Immune-related adverse events with immune checkpoint blockade: a comprehensive review. , 2016, European journal of cancer.

[119]  K. Winthrop,et al.  Infection Risk and Safety of Corticosteroid Use. , 2016, Rheumatic diseases clinics of North America.

[120]  R. Sullivan,et al.  Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders. , 2016, JAMA oncology.

[121]  R. Montironi,et al.  New toxicity profile for novel immunotherapy agents: focus on immune-checkpoint inhibitors , 2016, Expert opinion on drug metabolism & toxicology.

[122]  K. Flaherty,et al.  Prognostic Significance of Cutaneous Adverse Events Associated With Pembrolizumab Therapy. , 2015, JAMA oncology.

[123]  A. Daud,et al.  Pembrolizumab Cutaneous Adverse Events and Their Association With Disease Progression. , 2015, JAMA dermatology.

[124]  G. Gibney,et al.  Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes , 2015, Clinical Cancer Research.

[125]  S. Mori,et al.  Hepatitis B virus reactivation associated with antirheumatic therapy: Risk and prophylaxis recommendations. , 2015, World journal of gastroenterology.

[126]  M. Valsecchi.  Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. , 2015, The New England journal of medicine.

[127]  J. Kirkwood,et al.  Baseline circulating IL-17 predicts toxicity while TGF-β1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma , 2015, Journal of Immunotherapy for Cancer.

[128]  T. Barnetche,et al.  Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis , 2015, BMC Medicine.

[129]  E. Loftus,et al.  Systematic review: colitis associated with anti‐CTLA‐4 therapy , 2015, Alimentary pharmacology & therapeutics.

[130]  A. Amin,et al.  Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities. , 2015, Translational lung cancer research.

[131]  E. Lipson,et al.  Safety and efficacy of ipilimumab to treat advanced melanoma in the setting of liver transplantation , 2015, Journal of Immunotherapy for Cancer.

[132]  T. Schoeb,et al.  Th17 cells give rise to Th1 cells that are required for the pathogenesis of colitis , 2015, Proceedings of the National Academy of Sciences.

[133]  M. Postow.  Managing immune checkpoint-blocking antibody side effects. , 2015, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

[134]  P. Ascierto,et al.  Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. , 2015, The Lancet. Oncology.

[135]  J. Kench,et al.  Ipilimumab‐induced toxicities and the gastroenterologist , 2015, Journal of gastroenterology and hepatology.

[136]  E. Lipson,et al.  Nivolumab: targeting PD-1 to bolster antitumor immunity. , 2015, Future oncology.

[137]  A. Zwinderman,et al.  Vitiligo-like depigmentation in patients with stage III-IV melanoma receiving immunotherapy and its association with survival: a systematic review and meta-analysis. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[138]  J. Wolchok,et al.  Immune Checkpoint Blockade in Cancer Therapy. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[139]  J. Lünemann,et al.  Intravenous immunoglobulin in neurology—mode of action and clinical efficacy , 2015, Nature Reviews Neurology.

[140]  A. Giobbie-Hurder,et al.  Systemic High-Dose Corticosteroid Treatment Does Not Improve the Outcome of Ipilimumab-Related Hypophysitis: A Retrospective Cohort Study , 2014, Clinical Cancer Research.

[141]  R. Sullivan,et al.  Ipilimumab-induced hypophysitis: a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma. , 2014, The Journal of clinical endocrinology and metabolism.

[142]  A. Hauschild,et al.  Ipilimumab in patients with cancer and the management of dermatologic adverse events. , 2014, Journal of the American Academy of Dermatology.

[143]  E. Lipson,et al.  Successful administration of ipilimumab to two kidney transplantation patients with metastatic melanoma. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[144]  Y. Kong,et al.  Opportunistic Autoimmune Disorders Potentiated by Immune-Checkpoint Inhibitors Anti-CTLA-4 and Anti-PD-1 , 2014, Front. Immunol..

[145]  J. Wolchok,et al.  Pituitary Expression of CTLA-4 Mediates Hypophysitis Secondary to Administration of CTLA-4 Blocking Antibody , 2014, Science Translational Medicine.

[146]  J. Wolchok,et al.  Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution. , 2014, Endocrine-related cancer.

[147]  Avash Kalra,et al.  Early Administration of Infliximab for Severe Ipilimumab-Related Diarrhea in a Critically Ill Patient , 2014, The Annals of pharmacotherapy.

[148]  D. Teachey,et al.  Managing Cytokine Release Syndrome Associated With Novel T Cell-Engaging Therapies , 2014, Cancer journal.

[149]  R. Vonderheide,et al.  Mitigating the toxic effects of anticancer immunotherapy , 2014, Nature Reviews Clinical Oncology.

[150]  Antonio Pérez,et al.  Glucocorticoid‐induced hyperglycemia (糖皮质激素诱导的高血糖) , 2014, Journal of diabetes.

[151]  C. Lebbé,et al.  Ipilimumab-induced acute severe colitis treated by infliximab. , 2013, Melanoma research.

[152]  F. Nimmerjahn,et al.  Intravenous immunoglobulin therapy: how does IgG modulate the immune system? , 2013, Nature Reviews Immunology.

[153]  C. Berking,et al.  The Price of Tumor Control: An Analysis of Rare Side Effects of Anti-CTLA-4 Therapy in Metastatic Melanoma from the Ipilimumab Network , 2013, PloS one.

[154]  C. Oddis,et al.  Therapeutic advances in myositis , 2012, Current opinion in rheumatology.

[155]  A. Hauschild,et al.  Management of immune-related adverse events and kinetics of response with ipilimumab. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[156]  David C. Smith,et al.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. , 2012, The New England journal of medicine.

[157]  D. Mimouni,et al.  Mycophenolate mofetil for the management of autoimmune bullous diseases. , 2012, Immunology and allergy clinics of North America.

[158]  Y. Li,et al.  Mycophenolic Acid Differentially Impacts B Cell Function Depending on the Stage of Differentiation , 2011, The Journal of Immunology.

[159]  C. Elson,et al.  Th17 Cells Induce Colitis and Promote Th1 Cell Responses through IL-17 Induction of Innate IL-12 and IL-23 Production , 2011, The Journal of Immunology.

[160]  H. Hartung,et al.  Managing the risks of immunosuppression. , 2011, Current opinion in neurology.

[161]  J. Wolchok,et al.  Evaluation of serum IL-17 levels during ipilimumab therapy: Correlation with colitis. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[162]  G. Castellano-Tortajada,et al.  Reactivation of hepatitis B virus infection after cytotoxic chemotherapy or immunosuppressive therapy. , 2011, World journal of gastroenterology.

[163]  R. Kefford,et al.  Resolution of severe ipilimumab-induced hepatitis after antithymocyte globulin therapy. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[164]  M. Maio,et al.  The emerging toxicity profiles of anti-CTLA-4 antibodies across clinical indications. , 2010, Seminars in oncology.

[165]  D. Schadendorf,et al.  Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.

[166]  M. Carroll,et al.  Use of tumor necrosis factor α inhibitors in hepatitis B surface antigen-positive patients: a literature review and potential mechanisms of action , 2010, Clinical Rheumatology.

[167]  Petros P Sfikakis,et al.  The first decade of biologic TNF antagonists in clinical practice: lessons learned, unresolved issues and future directions. , 2010, Current directions in autoimmunity.

[168]  S. Kaveri,et al.  Intravenous Immunoglobulins in Autoimmune and Inflammatory Diseases , 2007, Annals of the New York Academy of Sciences.

[169]  H. Gürcan,et al.  Efficacy of Various Intravenous Immunoglobulin Therapy Protocols in Autoimmune and Chronic Inflammatory Disorders , 2007, The Annals of pharmacotherapy.

[170]  Jeffrey R Curtis,et al.  Population-based assessment of adverse events associated with long-term glucocorticoid use. , 2006, Arthritis and rheumatism.

[171]  S. Rosenberg,et al.  Skin reactions in a subset of patients with stage IV melanoma treated with anti-cytotoxic T-lymphocyte antigen 4 monoclonal antibody as a single agent. , 2006, Archives of dermatology.

[172]  A. Allison,et al.  Mechanisms of action of mycophenolate mofetil in preventing acute and chronic allograft rejection. , 2005, Transplantation.

[173]  W. Sewell,et al.  Clinical uses of intravenous immunoglobulin , 2005, Clinical and experimental immunology.

[174]  P. O'kelly,et al.  Acute interstitial nephritis: clinical features and response to corticosteroid therapy. , 2004, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[175]  S. Kaveri,et al.  Mechanisms of action of intravenous immunoglobulin in autoimmune and inflammatory diseases , 2003, Neurological Sciences.

[176]  A. Reimold,et al.  TNFalpha as therapeutic target: new drugs, more applications. , 2002, Current drug targets. Inflammation and allergy.

[177]  D. Orlinsky,et al.  Mycophenolate mofetil in autoimmune and inflammatory skin disorders. , 1999, Journal of the American Academy of Dermatology.

[178]  J. Cameron.  The treatment of lupus nephritis , 1989, Pediatric Nephrology.

[179]  J. Wolchok,et al.  Measuring Toxic Effects and Time to Treatment Failure for Nivolumab Plus Ipilimumab in Melanoma , 2018, JAMA oncology.

[180]  L. Heinzerling,et al.  Life-threatening Autoimmune Cardiomyopathy Reproducibly Induced in a Patient by Checkpoint Inhibitor Therapy. , 2018, Journal of immunotherapy.

[181]  D. Bonaduce,et al.  Immune Checkpoint Inhibitors and Cardiac Toxicity: An Emerging Issue. , 2018, Current medicinal chemistry.

[182]  T. Kikuchi,et al.  Mycophenolate mofetil as a therapeutic agent for interstitial lung diseases in systemic sclerosis. , 2018, Respiratory investigation.

[183]  Ji Sun,et al.  Pharmacokinetics and Pharmacodynamics of Immunotherapy , 2018 .

[184]  Douglas B. Johnson,et al.  Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[185]  S. Gettinger,et al.  Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study. , 2017, The Lancet. Oncology.

[186]  A. Palestine,et al.  Checkpoint inhibitor-induced uveitis: a case series , 2017, Graefe's Archive for Clinical and Experimental Ophthalmology.

[187]  T. Torigoe,et al.  Immune-related adverse events of immune checkpoint inhibitors. , 2017, Nihon Rinsho Men'eki Gakkai kaishi = Japanese journal of clinical immunology.

[188]  J. Soria,et al.  Association of Vitiligo With Tumor Response in Patients With Metastatic Melanoma Treated With Pembrolizumab. , 2016, JAMA dermatology.

[189]  J. Wolchok,et al.  Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[190]  S. Moschos,et al.  Next Steps in Immuno-Oncology: Enhancing Antitumor Effects Through Appropriate Patient Selection and Rationally Designed Combination Strategies. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[191]  J. Cadranel,et al.  [Autoimmune hepatitis]. , 2015, La Revue du praticien.

[192]  J. Keane,et al.  Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. , 2001, The New England journal of medicine.

[193]  Annie Heng,et al.  Cancer Management and Research Dovepress Real-world Impact of Education: Treating Patients with Ipilimumab in a Community Practice Setting , 2022 .